Literature DB >> 24041957

Glaucocalyxin A, a negative Akt regulator, specifically induces apoptosis in human brain glioblastoma U87MG cells.

Xian Xiao1, Weidong Cao, Xiaofan Jiang, Wei Zhang, Yongqiang Zhang, Bolin Liu, Jinxiang Cheng, Huiyong Huang, Junli Huo, Xiang Zhang.   

Abstract

Akt is becoming an attractive target in the development of anti-tumor agents. In the present study, we aimed to discover novel negative Akt regulators against malignant glioma. An Akt regulator screening platform performed in an Akt-GFP overexpression cell line was developed, and natural product library was screened and evaluated using this platform. In addition, the cytotoxic effect of the regulator was detected by MTT assay. Cell apoptosis was assayed by Hoechst 33342 staining and flow cytometry analysis. Afterwards, the apoptotic signaling pathway was investigated by western blot analysis. Glaucocalyxin A, isolated from Rabdosia japonica, was identified as a potent negative regulator of Akt. In human-derived malignant glioma U87MG cells, glaucocalyxin A inhibited Akt phosphorylation, suppressed proliferation, and promoted apoptosis in a dose-dependent manner, but not in normal glial cells. Furthermore, glaucocalyxin A activated caspase-3, decreased BAD phosphorylation, and reduced the expression of X-linked inhibitor of apoptosis protein. Taken together, these results indicated that glaucocalyxin A may become a promising candidate in the treatment of malignant glioma.

Entities:  

Keywords:  Akt regulator; apoptosis; glaucocalyxin A; glioblastoma

Mesh:

Substances:

Year:  2013        PMID: 24041957     DOI: 10.1093/abbs/gmt097

Source DB:  PubMed          Journal:  Acta Biochim Biophys Sin (Shanghai)        ISSN: 1672-9145            Impact factor:   3.848


  8 in total

1.  Glaucocalyxin A inhibits the growth of liver cancer Focus and SMMC-7721 cells.

Authors:  Lisha Tang; Xiaofeng Jin; Xiaohui Hu; Xiaoding Hu; Zulong Liu; Long Yu
Journal:  Oncol Lett       Date:  2015-12-03       Impact factor: 2.967

2.  Preparation and antitumor effects of glaucocalyxin A-γ-cyclodextrin clathrate.

Authors:  Chong Zhang; Yan Qu; Yan-Long Jia; Xiao-Jun Shang; Su-Ping Bai
Journal:  Int J Clin Exp Med       Date:  2015-08-15

3.  Glaucocalyxin A Ameliorates Myocardial Ischemia-Reperfusion Injury in Mice by Suppression of Microvascular Thrombosis.

Authors:  Xiaohui Liu; Dongzhou Xu; Yuxin Wang; Ting Chen; Qi Wang; Jian Zhang; Tao You; Li Zhu
Journal:  Med Sci Monit       Date:  2016-10-07

4.  Glaucocalyxin A suppresses multiple myeloma progression in vitro and in vivo through inhibiting the activation of STAT3 signaling pathway.

Authors:  Mei Li; Cailong Chen; Qian Wang; Xiaolu Jiang; Lanlan Tan; Ying Huang; Yan Zhang; Zubin Zhang
Journal:  Cancer Cell Int       Date:  2021-12-19       Impact factor: 5.722

Review 5.  Promising Therapeutic Candidate for Myocardial Ischemia/Reperfusion Injury: What Are the Possible Mechanisms and Roles of Phytochemicals?

Authors:  Cong Chen; Lin-Tong Yu; Bai-Ru Cheng; Jiang-Lin Xu; Yun Cai; Jia-Lin Jin; Ru-Li Feng; Long Xie; Xin-Yan Qu; Dong Li; Jing Liu; Yan Li; Xiao-Yun Cui; Jin-Jin Lu; Kun Zhou; Qian Lin; Jie Wan
Journal:  Front Cardiovasc Med       Date:  2022-02-17

6.  A novel strategy for the characterization of glaucocalyxin A metabolites in vivo and in vitro by UHPLC-Q-TOF-MS based on DDA and DIA data acquisitions.

Authors:  Wenjing Sun; Yiran Jin; Shuai Guan; Mengxin Yang; Miaoting Zhang; Jiali Hou; Yingfeng Du
Journal:  RSC Adv       Date:  2020-03-11       Impact factor: 4.036

7.  Glaucocalyxin A exerts anticancer effect on osteosarcoma by inhibiting GLI1 nuclear translocation via regulating PI3K/Akt pathway.

Authors:  Jianwei Zhu; Yang Sun; Ying Lu; Xiubo Jiang; Bo Ma; Lisha Yu; Jie Zhang; Xiaochen Dong; Qi Zhang
Journal:  Cell Death Dis       Date:  2018-06-13       Impact factor: 8.469

Review 8.  Mechanistic Pathways and Molecular Targets of Plant-Derived Anticancer ent-Kaurane Diterpenes.

Authors:  Md Shahid Sarwar; Yi-Xuan Xia; Zheng-Ming Liang; Siu Wai Tsang; Hong-Jie Zhang
Journal:  Biomolecules       Date:  2020-01-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.